How to Buy Coherus Oncology Stock
Coherus Oncology Inc
Coherus Oncology, Inc. , a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Coherus Oncology stock last closed at $1.57, up 2.55% from the previous day, and has increased 107.74% in one year. It has overperformed other stocks in the Biotechnology industry by 1.84 percentage points. Coherus Oncology stock is currently +121.13% from its 52-week low of $0.71, and -39.98% from its 52-week high of $2.62.
At the moment, there are 154.25M CHRS shares outstanding. The market cap of CHRS is $242.17M. In the past 24 hours, 1.38M CHRS shares were traded.
How to Buy Coherus Oncology Stock
Not sure how to invest in Coherus Oncology stock? Here's how.
- Figure out where to buy Coherus Oncology stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you choose where to buy Coherus Oncology stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Evaluate Coherus Oncology stock: The Coherus Oncology ticker symbol is CHRS. Is Coherus Oncology stock a good investment? Should you buy shares of CHRS? How do CHRS's underlying business fundamentals look? Do top analysts think Coherus Oncology is a good buy? Why has CHRS's stock price moved recently? (Hint: Our stock research website can help you evaluate if CHRS is a good stock to buy).
- Make your CHRS trade: Decide if you will purchase CHRS shares at the current market price or use a limit order to buy CHRS shares at a particular price.
- Keep tabs on your investment in CHRS: Create a watchlist to key updates about your position in Coherus Oncology shares.
Step 1: Figure out where to buy Coherus Oncology stock
You need a brokerage account in order to access the NASDAQ market and buy CHRS stock.
Our preferred brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you are able to buy CHRS stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on the greatest app to buy stocks, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring funds into your investment account.
Step 4: Evaluate Coherus Oncology stock
Once you have decided on the best place to buy Coherus Oncology stock, it's absolutely critical to analyze their stock before you invest, so you truly wrap your head around the risk and upside.
Coherus Oncology Numbers
Coherus Oncology Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CHRS's stock page.
Is CHRS stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CHRS's true value.
Using relative valuations measures:
- CHRS may be undervalued based on its P/E ratio of 0.96x, relative to Biotechnology industry P/E ratio of 18.28x
- CHRS may be undervalued based on its P/B ratio of 3.08x, relative to Biotechnology industry P/B ratio of 4.87x
You can do additional valuation research on CHRS's stock here.
CHRS Financial Overview
Pros:
- There are more short-term assets than short-term liabilities on the CHRS balance sheet.
- Total CHRS debt is lower than 5 years ago, relative to shareholder equity.
- CHRS profit margin has gone up from -413.3% to 397.3% in the past year.
- CHRS has $167.05M in cash and short term investments. This is enough to cover its annual cash burn of $170.57M.
- There are more short-term assets than long-term liabilities on the CHRS balance sheet.
Cons:
- CHRS has a relatively high debt to equity ratio of 2.38.
- CHRS has cash burn of 170573000. It does not have sufficient cash and short-term investments to cover this.
Is it a good time to buy CHRS stock, according to Wall Street analysts?
Out of 1 Equities analysts who track CHRS, the consensus analyst rating on Coherus Oncology is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Coherus Oncology stock forecast page.
CHRS Trading Indicators
CHRS Growth Metrics
Last year, CHRS revenue was $46.88M. Over the past 5 year, CHRS's revenue has grown by -36.18% per year. This was slower than the Biotechnology industry average of 30%.
You can research CHRS's earnings and revenue performance here.
What are CHRS executives and large shareholders up to?
In the last year, insiders at CHRS have sold more shares than they have bought.
Dennis M. Lanfear, President CEO of CHRS, was the latest CHRS insider to sell. They sold $18,350.45 worth of CHRS stock on Jan 20, 2026.
Learn more about who owns CHRS stock here.
Can I get consistent income from CHRS stock?
No, Coherus Oncology doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your CHRS trade
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, use a limit order.
Click the Open button and your broker will place the order.
If you want more help with investing in stocks on eToro, watch the helpful video below:
Step 6: Keep tabs on your investment in CHRS
Now that you own some shares in CHRS, you'll want to stay up-to-date on your shares.
Put CHRS on a watchlist to monitor your CHRS stock.
CHRS Feed
How to Buy Stock in Coherus Oncology
To reiterate, here are the 6 steps you need to take to buy Coherus Oncology stock right now:
- Figure out where to buy Coherus Oncology stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Coherus Oncology stock
- Make your CHRS trade
- Keep tabs on your investment in CHRS
If you require a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to watch your new investment in Coherus Oncology, hit the button below to create your watchlist.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.